Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225452 · ClinicalTrials.gov registry record
An Exosomal miRNA-based Liquid Biopsy for ICC Detection
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 535
- Enrollment target
NCT07225452: Completed study, sponsored by City of Hope Medical Center.
NCT07225452 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 535 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07225452 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 535 participants
- Enrollment target
Study Summary
Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need. The LUMIC study aims to develop a non-invasive liquid biopsy platform based on both exosomal microRNAs (exo-miRNAs) to detect intrahepatic cholangiocarcinoma with high sensitivity and specificity.
Primary Outcome
The proportion of true positive ICC cases correctly identified by the LUMIC assay.
Interventions
- DIAGNOSTIC_TEST Small RNA sequencing
- DIAGNOSTIC_TEST LUMIC assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-02-05 |
What the finished NCT07225452 record still lists
NCT07225452 is an observational study that tracks outcomes without assigning an intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Small RNA sequencing is the first listed.
NCT07225452 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07225452 about?
NCT07225452 is a clinical study titled "An Exosomal miRNA-based Liquid Biopsy for ICC Detection". Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need. The LUMIC study aims to develop a non-invasive liquid biopsy platform based on both exosomal microRNAs (exo-miRNA...
What is the current status of trial NCT07225452?
This trial is currently completed. The enrollment target is 535 participants. The study started on 2024-06-21. Estimated completion is 2026-02-05.
What interventions are being tested in trial NCT07225452?
The interventions under investigation include: Small RNA sequencing (DIAGNOSTIC_TEST), LUMIC assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07225452?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI